203 participants
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-09-01
- Start Date:
- 2022-10-18
- Completion:
- 2025-09-03
Conditions
- Hodgkin Lymphoma
Interventions
- BIOLOGICAL
- DRUG